Anjarium Biosciences AG

Four years after its launch, Swiss gene therapy pioneer Anjarium Biosciences AG has banked CHF55.5m ($61m) from a series A financing that will be used to develop innovative non-viral, tissue-targete

As venture capital financings for biopharmaceutical companies continues to head into record-breaking territory again in 2021, Illumina Ventures and Jeito Capital announced two new venture capital fund